CLINICAL_TRIALS
trial_result
· 2024-12-31
Clinical Trial Update: A Study of Belcesiran in Patients With AATLD [Phase 2]
Summary
A Phase 2 study of Belcesiran in patients with Alpha-1 antitrypsin deficiency has been terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 2 | Status: TERMINATED | Results posted: 2024-12-31